Adaptive clinical trials

Adaptive clinical trials design CRO

Pfizer and Roche are the latest pharma heavyweights to join Icon's consortium of drugmakers working to flesh out new technology for adaptive clinical trials, allowing study sponsors to react to results in real time and maximize efficacy.

Just three months after wrapping its latest merger, BioClinica has made another acquisition, snapping up Blueprint Clinical to expand its capabilities in the growing field of risk-based management.

As the industry embraces risk-based clinical trial monitoring, Parexel International is expanding its banner eClinical offering to help sponsors make data-driven decisions in the middle of a study.

CRO giant Icon has agreed to trade $143.5 million for Aptiv Solutions, looking to complement its own technology in complex trial design and expand its presence in Japan.

Icon, like most of the world's largest CROs, is investing in high-tech adaptive trial monitoring, and the company's latest offering allows investigators to comb through huge dumps of lab data in real time, tracking trial trends as they happen.

Drugmakers have misfired way more than hit their targets in developing new drugs for complex diseases such as Alzheimer's. Dr. Michael Krams, vice president and head of the neurology franchise at Johnson & Johnson ($JNJ), suggests that part of the problem lies in the way pharma companies have designed clinical trials, according to an article from Bio-IT World.

As clinical trials get more and more complex, Pharmaceutical Product Development has reached out to technology consultancies Tessella and Berry Consultants to use FACTS, adaptive trial software that lets study designers simulate trials in their early planning stages.

As drug developers seek efficient ways to study new treatments for complex disease, Pharmaceutical Product Development has tapped adaptive clinical trials software from technology consultancies Tessella and Berry Consultants.

Aptiv Solutions has grabbed a key piece to the tech puzzle it has been assembling to provide drug and device developers with adaptive clinical trials. The Reston, VA-based CRO, which launched last...

You might also like
Adaptive 2-Stage Design Supporting the Fulyzaq® Approval
Adaptive 2-Stage Design Supporting the Fulyzaq® Approval
Bayesian Adaptive Methods for Clinical Trials, Author
Bayesian Adaptive Methods for Clinical Trials, Author ...
Bayesian Adaptive Trial Design—Dr. Roger Lewis, April 26
Bayesian Adaptive Trial Design—Dr. Roger Lewis, April 26 ...

Popular Q&A

avatar
What is academic researcher perspective on CRO involvement in clinical trials?

To me, it is a positive step which allows the scientist to spend more time engaged in mastering his discipline at a deep level, rather than the formalism of the experiments that he wants to conduct.

Related Posts